Details for New Drug Application (NDA): 018285
✉ Email this page to a colleague
The generic ingredient in VISKEN is pindolol. There are eleven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the pindolol profile page.
Summary for 018285
Tradename: | VISKEN |
Applicant: | Novartis |
Ingredient: | pindolol |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 018285
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Sep 3, 1982 | TE: | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Sep 3, 1982 | TE: | RLD: | Yes |
Expired US Patents for NDA 018285
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | VISKEN | pindolol | TABLET;ORAL | 018285-001 | Sep 3, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | VISKEN | pindolol | TABLET;ORAL | 018285-002 | Sep 3, 1982 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription